TRIAL DETAIL

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Drug:
Trial Name:
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Ongoing, but not recruiting
Phase:
2
Start Date 12/05/2007
Age of Trial (yrs) 14
Treatment Phase:
First-line
Drug Category:
KIT/PDGFRA inhibitor + SRC inhibitor
Strategy:
Block KIT + Block KIT Signal Path
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
CDR0000577496, SWS-SAKK-56/07, EU-20789, EUDRACT-2007-002047-24
Sponsor:
Swiss Group for Clinical Cancer Research
Patient Contact:
See site contact info below
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
This phase II trial studied how well dasatinib works as first-line therapy in treating patients with gastrointestinal stromal tumors. Final trial results have been reported (see link in Trial Results).

Trial Links

Trial Results

 

Drug Information

Dasatinib inhibits KIT D816V mutation-an imatinib-resistant activating mutation
 
Sprycel.com
 
Sprycel reimbursement support (Destination Access)
 
Sprycel prescribing information (PDF)
 
Dasatinib inhibits PDGFRA D842V mutation - Debiec-Rychter - 2008
 
Dasatinib inhibits activity of wild-type, juxtamembrane and activation loop mutant KIT (Heinrich, et al)
 
FDA drug information page (technical information about the drug approval, etc)
 
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib (mentions that dasatinib levels are highly affected by PPIs).
 
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
 
FDA: Increased Pulmonary Arterial Hypertension Risk Seen With Dasatinib
 
FDA website: Sprycel (dasatinib): Drug Safety Communication - Risk of Pulmonary Arterial Hypertension
 
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities
 
Disintegration of chemotherapy tablets (including dasatinib) for oral administration in patients with swallowing difficulties
 
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
 

Trial Sites

Name
Address
City
State
Zip
Country
Lausanne
CH-1011
Switzerland
Helsinki
FIN-00029
Finland
Strasbourg
67065
France
Lyon
69008
France
229 Cours Argonne
Bordeaux
Gironde
33076
France
Villejuif
Val de Narne
94805
France
Hufelandstr. 55
Essen
45122
Germany
Zurich
CH-8063
Switzerland
Geneva
CH-1211
Switzerland
Basel
CH-4031
Switzerland
Baden
CH-5404
Switzerland
Bruderholz
CH-4101
Switzerland
Chur
CH-7000
Switzerland
Liestal
CH-4410
Switzerland
Zurich
CH-8002
Switzerland
Basel
CH-4016
Switzerland
Zurich
CH-8091
Switzerland
St. Gallen
CH-9007
Switzerland